Aspira Women's Health (AWHL) AI Stock Analysis

• Market Cap: $22.60M
• Dividend Yield: N/A
• Average Volume (3M): 100.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: 4.17%
• EPS Growth: 68.47%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.13
• Shares Outstanding: 42,655,920
• 10 Day Avg. Volume: 120,018
• 30 Day Avg. Volume: 100,391
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.29
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.37 ▲(3.06% Upside)

The overall stock score is primarily driven by poor financial performance and valuation metrics, reflecting significant risks due to negative equity and ongoing losses. Technical analysis indicates bearish momentum, further impacting the score. Positive corporate events provide some support but are insufficient to offset the financial challenges.

Positive Factors

Market Upgrade

The upgrade to the OTCQX market enhances Aspira's visibility and credibility, potentially attracting more investors and improving market perception.

Funding Raise

The $3.06 million funding provides essential capital for Aspira to support its growth plans and expand its product pipeline, strengthening its market position.

Gross Profit Margin Improvement

The significant improvement in gross profit margin indicates effective cost management, enhancing the company's ability to generate profit from its operations.

Negative Factors

Negative Equity

Negative equity suggests financial instability, with liabilities exceeding assets, posing a risk to Aspira's long-term financial health and solvency.

Unprofitability

Ongoing unprofitability and negative net income highlight challenges in achieving sustainable financial performance, impacting long-term viability.

Persistent Cash Flow Deficits

Consistent negative cash flow indicates difficulty in generating cash internally, limiting Aspira's ability to fund operations and growth without external financing.

Aspira Women's Health Business Overview & Revenue Model

Company Description

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

How the Company Makes Money

Aspira Women's Health generates revenue primarily through the sale of its diagnostic tests, such as OVA1 and Overa, to healthcare providers, hospitals, and laboratories. The company operates on a fee-for-service model, where they charge for each test performed. In addition, AWHL may benefit from reimbursement agreements with insurance companies, allowing healthcare providers to receive compensation for the tests administered to patients. Strategic partnerships with healthcare institutions and collaborations with research organizations also contribute to revenue growth, as they can expand market access and validate the efficacy of AWHL's products. Furthermore, the company may explore opportunities in government grants or funding related to women's health initiatives, further diversifying its income streams.

Aspira Women's Health Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Aspira Women's Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWHL, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.48, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.61 is Neutral, neither overbought nor oversold. The STOCH value of 50.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AWHL.

Aspira Women's Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	57 Neutral	$32.51M	-16.60	-9.76%	―	30.95%	59.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDSX	51 Neutral	$60.46M	-1.42	-302.55%	―	22.29%	31.93%
VNRX	42 Neutral	$38.24M	-1.37	―	―	14.48%	36.83%
MYNZ	41 Neutral	$7.52M	―	―	―	―	―
AWHL	40 Underperform	$22.60M	-1.12	―	―	4.17%	68.47%
TRIB	40 Underperform	$18.05M	-0.34	―	―	-4.35%	-6.31%

Aspira Women's Health Corporate Events

Aspira Women’s Health Upgrades to OTCQX Market

On October 14, 2025, Aspira Women’s Health Inc. transitioned from the OTCQB® Venture Market to the more prestigious OTCQX market, trading under the symbol ‘AWHL.’ This upgrade signifies a strategic advancement for the company, potentially enhancing its visibility and credibility within the financial markets.

Aspira Women’s Health Amends Securities Agreement

On March 5, 2025, Aspira Women’s Health Inc. entered into a securities purchase agreement with existing accredited shareholders for a private placement of $1,370,000 in Senior Secured Convertible Promissory Notes, which have since been converted into units of common stock and warrants. On September 19, 2025, the company amended the agreement to exclude certain securities from ‘Exempt Issuance,’ required filing a registration statement, and allowed purchasers to appoint directors to the board. The amendment also adjusted terms of the warrants, including a fixed exercise price and extended term.

Aspira Women’s Health Raises $3.06 Million in Funding

On September 16, 2025, Aspira Women’s Health Inc. entered into securities purchase agreements with investors, resulting in a private placement of common stock and warrants, raising approximately $2.95 million. The company plans to use these funds for working capital and general corporate purposes. This financial move, along with an additional $112,500 from warrant exercises, provides Aspira with a total equity capital infusion of $3.06 million. This capital will support Aspira’s ongoing commercial activities and growth plans, as the company focuses on executing its strategic goals and expanding its innovative product pipeline in women’s health diagnostics.